Home
News
Press Releases and Articles
Calendar of Events
How to Help
Gates Foundation Grant to GAELF
The Global Alliance
Global Alliance History
Goals
Global Alliance Structure
Executive Group
Partnerships
GAELF Logo
LF Webring
About LF
What is LF?
How is LF Contracted?
How is LF Diagnosed?
Prevent/Eliminate LF
Manage LF
LF and Children
Additional Treatment Benefits
LF Slideshow
In Depth Disease Info
Where is LF?
Countries and Map List
Moving Forward
Starting Out
Success Stories
Progress and Plans
Elimination Strategy
Operational Research
Progress to Date
Economics of LF
Return on Investment
The Way Ahead
Highlighted Programmes
   Burkina Faso
   Sri Lanka

For the Media
Press Release Archive
Press Kits
Photos
Articles
Video Clips
Media Contacts
FAQs
Publications
LF News
Annual Reports
General Publications
Training Material
Videos
Journal Articles & Other Pubs
EG Updates
Gates Foundation

Partnerships

The core strength of the Global Alliance to Eliminate Lymphatic Filariasis lies in its ability to bring together various partners in the quest to eliminate lymphatic filariasis. Each partner joins with a different mandate and all share a common goal: to create a future free of lymphatic filariasis. With more than forty partners already, the growing Global Alliance benefits from a broad and deep experience of health, development, and philanthropic experience.

Endemic countries lead the Global Alliance by implementing the strategy, identifying operational research needs, and monitoring and evaluating progress.

  • National Ministries of Health of the 83 endemic countries

International Organisations provide expertise to support national programmes in preparing national plans, mapping disease distribution, training health personnel both in drug distribution and disability prevention and control activities, social mobilization, and monitoring and evaluation.

Private Sector companies provide supplies and drugs, free or at-cost, for mass drug administration campaigns, promote advocacy, support academia and facilitate programme development.


In 1998, the coalition was given a powerful boost when GlaxoSmithKline (at the time SmithKline Beecham) announced its commitment to collaborate with the World Health Organization, in the form of a unique partnership between the private sector and the public sector, by donating albendazole (one of the drugs used against lymphatic filariasis) free of charge for as long as necessary. The two organisations pledged to work together closely to undertake this massive international public health effort. Subsequently, Merck & Co., Inc. pledged to expand its ongoing Mectizan® Donation Program for onchocerciasis (river blindness) to cover treatment of lymphatic filariasis with Mectizan® (ivermectin) in all African countries where the two diseases co-exist. The donations will enable countries which are in need, but which are without the necessary resources, to acquire the drugs and to pursue their national elimination programmes.
 

International Development Agencies and Foundations have pledged funds to support the implementation of national LF elimination programmes.

Advocacy and resource mobilization partners

Non-governmental development organisations complement the efforts of the national Ministries of Health in implementing different components of the programmes within their specific competence and scope.

Academic and research institutions strengthen the scientific basis, test new tools and strategies, provide postgraduate human capacity development and carry out operational research

 

© Global Alliance to Eliminate Lymphatic Filariasis